Last reviewed · How we verify

SHR7280;Ganirelix Acetate Injection simulant — Competitive Intelligence Brief

SHR7280;Ganirelix Acetate Injection simulant (SHR7280;Ganirelix Acetate Injection simulant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH antagonist. Area: Reproductive/Fertility.

phase 3 GnRH antagonist GnRH receptor Reproductive/Fertility Small molecule Live · refreshed every 30 min

Target snapshot

SHR7280;Ganirelix Acetate Injection simulant (SHR7280;Ganirelix Acetate Injection simulant) — Jiangsu HengRui Medicine Co., Ltd.. Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SHR7280;Ganirelix Acetate Injection simulant TARGET SHR7280;Ganirelix Acetate Injection simulant Jiangsu HengRui Medicine Co., Ltd. phase 3 GnRH antagonist GnRH receptor
Lupron leuprorelin Accord Healthcare S.L.U. marketed Gonadotropin Releasing Hormone Receptor Agonist GnRH receptors 1985-01-01
Micronor norethisterone Johnson & Johnson marketed Progestin GnRH receptors 1962-01-01
GnRH antagonist-Cetrorelix GnRH antagonist-Cetrorelix University of Edinburgh marketed GnRH antagonist GnRH receptor
Lupron Trigger Lupron Trigger Weill Medical College of Cornell University marketed GnRH agonist GnRH receptor
Cetrorelix and Leuprolide Cetrorelix and Leuprolide Instituto Valenciano de Infertilidad, IVI VALENCIA marketed GnRH antagonist and GnRH agonist combination GnRH receptor
Ultra-Long GnRH Agonists + Letrozole Ultra-Long GnRH Agonists + Letrozole University of Palermo marketed GnRH agonist + aromatase inhibitor combination GnRH receptor; aromatase (CYP19A1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (GnRH antagonist class)

  1. Jiangsu HengRui Medicine Co., Ltd. · 2 drugs in this class
  2. Instituto Valenciano de Infertilidad, IVI VALENCIA · 2 drugs in this class
  3. AEterna Zentaris · 2 drugs in this class
  4. El Shatby University Hospital for Obstetrics and Gynecology · 1 drug in this class
  5. Eugonia · 1 drug in this class
  6. Instituto de Investigacion Sanitaria La Fe · 1 drug in this class
  7. Merck KGaA, Darmstadt, Germany · 1 drug in this class
  8. Rabin Medical Center · 1 drug in this class
  9. Sumitomo Pharma Switzerland GmbH · 1 drug in this class
  10. University of Edinburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SHR7280;Ganirelix Acetate Injection simulant — Competitive Intelligence Brief. https://druglandscape.com/ci/shr7280-ganirelix-acetate-injection-simulant. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: